Kymera Therapeutics to Participate in Upcoming Fourth Quarter Investor Conferences

Rhea-AI Summary

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company, announced its participation in several upcoming virtual investor conferences. Notable events include a panel discussion at the UBS conference on November 1, 2021, and fireside chats at the Credit Suisse and Stifel healthcare conferences on November 11 and 15, respectively. Kymera focuses on targeted protein degradation, with its Pegasus™ platform addressing high-impact targets for immune-inflammatory diseases and cancers. For more details, webcasts will be available on their website.

WATERTOWN, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will participate in several upcoming virtual investor conferences:

• UBS: Panel discussion: “TPD from Concept to Clinic: What Have We Learned So Far From Clinical Data?” on November 1, 2021 at 11:00 a.m. ET.
• Credit Suisse 30th Annual Virtual Healthcare Conference: Fireside chat on November 11, 2021 at 1:00 p.m. ET.
• Stifel 2021 Virtual Healthcare Conference: Fireside chat on November 15, 2021 at 8:40 a.m. ET.
• Guggenheim Healthcare Talks | Idea Forum | 3rd Annual Neuro/Immunology Day: Fireside chat on November 16, 2021 at 11:00 a.m. ET.
• Piper Sandler 33^rd Annual Healthcare Conference on November 30, 2021: Fireside chat available to conference participants on-demand.
• Evercore ISI 4^th Annual HealthCONx Conference: Fireside chat, time TBD, December 1-2, 2021.

Presentation webcasts will be available under "Events and Presentations" in the Investors section of the Company's website at www.kymeratx.com. Archived webcast replays will be available on the website for approximately 30 days.

About Kymera Therapeutics
Kymera Therapeutics (Nasdaq: KYMR) is a clinical-stage biopharmaceutical company founded with the mission to discover, develop, and commercialize transformative therapies while leading the evolution of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera’s Pegasus™ platform enables the discovery of novel small molecule degraders designed to harness the body’s natural protein recycling machinery to degrade disease-causing proteins, with a focus on undrugged nodes in validated pathways currently inaccessible with conventional therapeutics. Kymera’s initial programs are IRAK4, IRAKIMiD, and STAT3, each of which addresses high impact targets within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors. Kymera’s goal is to be a fully integrated biopharmaceutical company at the forefront of this new class of protein degrader medicines, with a pipeline of novel degrader medicines targeting disease-causing proteins that were previously intractable.

Founded in 2016, Kymera is headquartered in Watertown, Mass. Kymera has been named a “Fierce 15” biotechnology company by FierceBiotech and has been recognized by the Boston Business Journal as one of Boston’s “Best Places to Work.” For more information about our people, science, and pipeline, please visit www.kymeratx.com or follow us on Twitter or LinkedIn.

Investor Contact:
Bruce Jacobs
Chief Financial Officer
investors@kymeratx.com
857-285-5300

Chris Brinzey
Managing Director, Westwicke
chris.brinzey@westwicke.com
339-970-2843

Media Contact:
Tyler Gagnon
Director, Corporate Communications
tgagnon@kymeratx.com
508-904-9446

FAQ

What conferences will Kymera Therapeutics participate in during November 2021?

Kymera Therapeutics will participate in several virtual investor conferences, including UBS on November 1, Credit Suisse on November 11, Stifel on November 15, Guggenheim on November 16, Piper Sandler on November 30, and Evercore ISI on December 1-2, 2021.

What is the focus of Kymera Therapeutics' research?

Kymera Therapeutics focuses on targeted protein degradation to develop therapies for immune-inflammatory diseases and cancers, utilizing their Pegasus™ platform.

When is the UBS panel discussion featuring Kymera Therapeutics?

The UBS panel discussion titled 'TPD from Concept to Clinic: What Have We Learned So Far From Clinical Data?' is scheduled for November 1, 2021, at 11:00 a.m. ET.

How can investors access Kymera Therapeutics' conference presentations?

Investors can access Kymera Therapeutics' presentation webcasts under 'Events and Presentations' on their website, with archived replays available for approximately 30 days.

What is the significance of Kymera Therapeutics' Pegasus™ platform?

Kymera's Pegasus™ platform is crucial for discovering novel small molecule degraders aimed at degrading disease-causing proteins in previously unreachable therapeutic areas.